The German health authorities have agreed to an increase in the price of Cambridge UK medical technology used to treat Multiple Sclerosis.
GW Pharmaceuticals, which has a major operation in Histon at the heart of the UK BiomedTech cluster, has revealed that agreement has been reached for a revised and mutually-acceptable reimbursement price for Sativex®.
The deal was agreed between Almirall S.A. – GW’s commercial partner in Germany – and the German National Association of Statutory Health Insurance Funds (GKV-SV).
The new agreement has resulted in an increase to the previously reduced price imposed by the German authorities in March which Almirall had considered to be unacceptable.
Justin Gover, GW’s CEO said: “We are pleased to have a positive outcome to discussions that result in an acceptable reimbursement price in Germany – Europe’s largest potential market for Sativex®.
“This agreement ensures that people suffering from Multiple Sclerosis spasticity in Germany will have long-term access to this important medicine.”
It is estimated that approximately 4,000 patients are currently being treated with Sativex in Germany.
Farid Taha, general manager of Almirall Hermal Company, added: “Almirall is committed to meeting the needs of MS patients and this is the reason we have been determined over recent months to achieve an appropriate resolution of the reimbursement price in Germany.
“Sativex represents an important advance in the symptomatic treatment of MS spasticity and this new agreement provides doctors and patients in Germany with the necessary assurance that Sativex represents not only a recognised therapeutic benefit, but will also be available on prescription for the long-term.”
For the original article, please click here http://www.businessweekly.co.uk/biomedtech-/15923-germany-agrees-to-raise-price-of-cambridge-ms-drug